Does obesity affect treatment response to secukinumab and its survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry
Mod Rheumatol.2023 doi 10.1093/mr/road061 Epub ahead of print
This observational study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients.
Cohorts in this study included AS patients based on the TURKBIO Registry between 2018 and 2021. Patients were divided into three groups: normal (BMI<25 kg/m²), overweight (BMI:25-30 kg/m²), and obese (BMI≥30 kg/m²).
Administration of secukinumab subcutaneously resulted in BASDAI50 response of 51.4% in normal-weight patients, 33.3% in overweight, and 27% in obese patients (p≥0.05). No statistically significant difference was observed in BASDAI50 at 3 and 12 months and ASAS20, ASAS40, ASDAS-LDA at 3, 6, and 12 months between the groups, although obese patients had numerically lower responses.
Keywords:
